Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Metabolic Effects of Copper in Intact Cells: Comparative Activity of Cupric Chloride and the Cupric Chelate of Kethoxal Bis(thiosemicarbazone)

BARBARA A. BOOTH and ALAN C. SARTORELLI
Molecular Pharmacology May 1967, 3 (3) 290-302;
BARBARA A. BOOTH
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALAN C. SARTORELLI
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The exposure of sarcoma 180 ascites cells to the cupric chelate [Cu(II)KTS] of kethoxal bis(thiosemicarbazone) (KTS) resulted in the death of a large proportion of the cell population; both the ligand portion of the molecule, KTS, and cupric chloride were less toxic. Cells isolated from mice treated with Cu(II)KTS contained considerably greater amounts of copper than did those cells exposed to the same number of gram-atoms of copper presented as either copper chloride or copper stearate. The results suggested that the relatively lipidsoluble chelate-form of copper was more readily assimilated. Dissociation of Cu(II)KTS occurred within neoplastic cells, and this resulted in a relatively rapid loss from the cells of the ligand portion, KTS. In contrast, the copper derived from Cu(II)KTS persisted for a much longer period of time. The relationship of nucleic acid and protein synthesis to the phenomenon of cell death induced by these agents was assessed by measuring the effects of the compounds on these metabolic processes. The formation of DNA was more sensitive to the inhibitory action of Cu(II)KTS, CuCl2, and KTS, than were either the syntheses of RNA or protein. In agreement with the cellular toxicity, Cu(II)KTS caused more pronounced depression of the incorporation of isotopic precursors into DNA than did either CuCl2 or KTS. The copper present in cells treated with Cu(II)KTS induced at least three metabolic blocks on the pathways of DNA biosynthesis. The most sensitive site was measured by the incorporation of thymidine-3H into DNA and presumably was the result of the loss of activity of thymidine kinase. The findings obtained using a variety of isotopic precursors of DNA as biochemical probes suggested that the intracellular localization of copper derived from Cu(II)KTS differed from that of CuCl2.

ACKNOWLEDGMENTS The authors wish to thank Dr. Harold G. Petering, formerly of the Upjohn Company, for generous supplies of kethoxal bis(thiosemicarbazone) and its cupric chelate and Miss Sheila J. Feld, Miss Florence C. Dunmore, and Miss Lynn A. Bon Tempo for capable assistance. This investigation was supported by U. S. Public Health Service Grant CA-02817 from the National Cancer Institute.

  • Copyright ©, 1967, by Academic Press Inc.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 3, Issue 3
1 May 1967
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic Effects of Copper in Intact Cells: Comparative Activity of Cupric Chloride and the Cupric Chelate of Kethoxal Bis(thiosemicarbazone)
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolic Effects of Copper in Intact Cells: Comparative Activity of Cupric Chloride and the Cupric Chelate of Kethoxal Bis(thiosemicarbazone)

BARBARA A. BOOTH and ALAN C. SARTORELLI
Molecular Pharmacology May 1, 1967, 3 (3) 290-302;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolic Effects of Copper in Intact Cells: Comparative Activity of Cupric Chloride and the Cupric Chelate of Kethoxal Bis(thiosemicarbazone)

BARBARA A. BOOTH and ALAN C. SARTORELLI
Molecular Pharmacology May 1, 1967, 3 (3) 290-302;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • EIPA, HMA and SMN2 gene regulation
  • Clc-2 has minor role in intestinal Cl- secretion
  • Resveratrol acts as an NR4A1 antagonist in lung cancer.
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics